Does Selank need a reducing agent in buffer?

No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.

Is Selank less light-sensitive than other peptides?

It lacks the methionine whose photo-accelerated oxidation drives that concern elsewhere. Dark storage remains sensible practice but the specific liability is absent.

Why avoid shaking the vial?

Shaking generates an air-liquid interface where peptides denature. Foam is the visible evidence. Swirl instead.

Selank (Tuftsin Analogue)

Selank Storage, Stability and Reconstitution

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-232 cited sources

Selank is supplied lyophilised and is most stable in that state, stored cold, dry and protected from light. Unusually among research peptides it has neither cysteine nor methionine, so disulfide chemistry and methionine oxidation — the two most common degradation routes — do not apply.

Key facts

Supplied as: White lyophilised powder
Disulfide risk: None — no cysteine
Oxidation risk: Low — no methionine
Deamidation risk: None — no Asn or Gln
Main route: Hydrolysis, resisted by three prolines
Lyophilised storage: Cold, dry, dark
Freeze-thaw: Avoid by aliquoting

Why lyophilised is the stable state

Freeze-drying removes water, and water participates in peptide-bond hydrolysis. A dry powder held cold has limited routes to degrade. This is general to research peptides rather than specific to Selank, and it is why the condition of material on arrival matters — a warm transit is time spent in a less protected state.

What does not apply here

Most peptide handling guidance is written around two liabilities. Cysteine forms and scrambles disulfide bonds, requiring reducing agents and careful buffer choice. Methionine oxidises to the sulfoxide, adding 16 Da, which is why dark and cold storage is emphasised so heavily for peptides such as MOTS-c and Semax. Selank has neither residue, and no asparagine or glutamine either, so deamidation is also off the table.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

What is left

Hydrolysis of the peptide backbone, and physical loss through adsorption to container surfaces — a real concern for very small quantities of a highly charged peptide. The three prolines resist enzymatic cleavage well, but proline does not protect against simple chemical hydrolysis in solution over time. Cold, dry and dark remains the correct storage regime; the reason is different from the usual one.

Reconstitution

Bacteriostatic water — sterile water preserved with 0.9% benzyl alcohol — is the usual diluent for research peptides, permitting repeated entry over a limited window. Introduce solvent gently against the vial wall rather than directing it onto the powder, and swirl rather than shake. Shaking creates an air-liquid interface at which peptides denature; foaming is the visible sign it has happened.

After reconstitution

Aliquot into single-use volumes rather than freeze-thawing repeatedly. Each cycle concentrates solutes at the advancing ice boundary and exposes the peptide to interfaces it tolerates poorly. Selank's small size and high solubility make it more forgiving than most, but repeated cycling is still avoidable damage.

Signs of a problem

Visible particulates, cloudiness or discolouration in a reconstituted solution mean the material should not be relied on for a measurement. Given how hydrophilic Selank is, difficulty dissolving at a concentration it previously tolerated is itself a signal that something has changed.

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does Selank need a reducing agent in buffer?: No. Reducing agents address disulfide chemistry, and there is no cysteine in the sequence.
Is Selank less light-sensitive than other peptides?: It lacks the methionine whose photo-accelerated oxidation drives that concern elsewhere. Dark storage remains sensible practice but the specific liability is absent.
Why avoid shaking the vial?: Shaking generates an air-liquid interface where peptides denature. Foam is the visible evidence. Swirl instead.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum